Clinical Trial Update: BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy [Phase 2]

View source ↗

Summary

Biogen's BG00010 (Neublastin) completed a Phase 2 multiple-dose adaptive design trial in participants with painful lumbar radiculopathy. The study also encompas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lumbar Radiculopathy
• Radiculopathy
• Sciatica

Drugs mentioned

• BG00010 (Neublastin) (BG00010)

Snippet

Sponsor: Biogen | Conditions: Painful Lumbar Radiculopathy, Sciatica | Phase 2 | Status: COMPLETED